ReviewDermatology and therapy2017
Current and Emerging Medical Therapies for Primary Hyperhidrosis.
Review in Dermatology and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Radiofrequency in the treatment of primary hyperhidrosis: systematic review and meta-analysis.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020Pooled it
- Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study.The Journal of dermatology · 2022Trial
- A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.The British journal of dermatology · 2021Trial
- Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis.Clinical pharmacokinetics · 2021Trial
- Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.Pediatric dermatology · 2020Trial
- A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.American journal of clinical dermatology · 2019Trial
- Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.American journal of clinical dermatology · 2019Trial
- Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.Pediatric dermatology · 2019Trial
- Don't Sweat It: Cannabinoid CB1 Receptors Reduce Sweating in a Mouse Model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Primary hyperhidrosis: an updated review.Drugs in context · 2025Review
- Anisocoria in patients with hyperhidrosis: A case series for the primary care physician.Journal of family medicine and primary care · 2024Article
- Topical Oxybutynin 3% Gel Versus Aluminum Chloride 15% Lotion in Treatment of Primary Focal Hyperhidrosis.Dermatology practical & conceptual · 2023Article
- Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics.Dermatology and therapy · 2022Review
- Microneedling Delivery of Botulinum Toxin Versus Intradermal Injection in the Treatment of Facial Hyperhidrosis.The Journal of clinical and aesthetic dermatology · 2022Article
- Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities.Postepy dermatologii i alergologii · 2022Review
- [Current status and prospects of clinical application of liposuction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2022Review
- Effectiveness of unilateral sequential video-assisted sympathetic chain blockage for primary palmar hyperidrosis in children and adolescents.Frontiers in pediatrics · 2022Article
- Bilateral one-stage single-port sympathicotomy in primary focal hyperhidrosis, a prospective cohort study: treat earlier?Journal of cardiothoracic surgery · 2021Article
- Treatment Patterns, Depression, and Anxiety Among US Patients Diagnosed with Hyperhidrosis: A Retrospective Cohort Study.Dermatology and therapy · 2020Article
- Differences in subjective and objective evaluation of hyperhidrosis. Study among medical students.Postepy dermatologii i alergologii · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperhidrosis is defined as the production of sweat beyond what is physiologically necessary to maintain thermal homeostasis. This disease state may (and typically does) have a significant impact on the patient's quality of life. Medications including antiperspirants, anticholinergics, and botulinum toxin have been shown to be effective in the management of hyperhidrosis. Several medical device technologies have also proven to be effective. This review article will explore the current and emerging pharmacological and medical device treatments for hyperhidrosis and provide a framework for treating patients who suffer with primary forms of hyperhidrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.